Ganciclovir-sensitive acute graft-versus-host disease in mice receiving herpes simplex virus-thymidine kinase-expressing donor T cells in a bone marrow transplantation setting

Transplantation

Volumn 69, Issue 4, 2000, Pages 503-508

  Contassot, Emmanuel ^a   Ferrand, Christophe ^a   Angonin, Régis ^b   Cohen, Jose L ^c   De Carvalho Bittencourt, Marcelo ^a   Lorchel, Fabrice ^b   Laithier, Véronique ^a   Cahn, Jean Yves ^b   Klatzmann, David ^d   Herve, Patrick ^a   Tiberghien, Pierre ^a,e  

^a Etablissement de Transfus Sanguine   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c Génopoïétic   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e Immuno Molec Therapeut Laboratory   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX VIRUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 0034063837     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200002270-00007     Document Type: Article

References (19)

1. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120.
2. Tiberghien P. Use of suicide genes in gene therapy. J Leukocyte Biol 1994; 56: 203.
3. Kit SW, Leung WC, Jorgensen GN, Dubbs DR. Distinctive properties of thymidine kinase isozymes induced by human and avian herpes virus. Int J Cancer 1974; 14: 598.
4. Tiberghien P, Reynolds CW, Keller J, et al. Ganciclovir treatment of herpes simplex kinase-transduced primary T-lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 1994; 84: 1333.
5. Robinet E, Certoux JM, Ferrand C, et al. A closed culture system for the ex vivo transduction and expansion of human T lymphocytes. J Hematother 1998; 7: 205.
6. Tiberghien P, Cahn JY, Brion A, et al. Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a phase I study. Human Gene Ther 1997; 8: 615.
7. Bordignon C, Bonini C, Verzeletti S, et al. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther 1995; 6: 813.
8. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor T lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719.
9. Cohen JL, Boyer O, Salomon B, et al. Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood 1997; 89: 4636.
10. Helene M, Lake-Bullock MH, Bryson JS, Jennings CD, Kaplan AM. Inhibition of graft-versus-host disease: use of a T cell-controlled suicide gene. J Immunol 1997; 158: 5079.
11. Cohen JL, Boyer O, Salomon B, et al. Fertile homozygous transgenic mice expressing a functional truncated herpes simplex thymidine kinase delta TK gene. Transgenic Res 1998; 7: 321.
12. Salomon B, Maury S, Loubière L, Caruso M, Onclercq R, Klatzmann D. A truncated herpes simplex virus thymidine kinase phosphorylates thymidine and nucleoside analogs and does not cause sterility in transgenic mice. Mol Cell Biol 1995; 10: 5322.
13. Lerner KG, Kao GF, Storb R. Histopathology of the graft-versus-host reaction in human recipients of marrow from HLA matched sibling donor. Transplant Proc 1974; 6: 367.
14. Sale GE, Shulman HM. The pathology of bone marrow transplantation. Masson Publishing USA, New York City, 1984: 265.
15. Fletcher C, Sawchuk R, Chinnock B, Miranda P, Balfour HH. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 1986; 40: 281.
16. Ferrara JLM, Guyillen FJ, Van Dicjkin PJ, et al. Evidence that granular lymphocytes of donor origin mediate acute graftversus-host disease. Transplantation 1989; 47: 50.
17. Piguet PF, Grau GE, Allet B, Vassali P. Tumor necrosis factor/ cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987; 166: 1280.
18. Cheng Y, Huang E, Lin J, et al. Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpes viruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci USA 1983; 80: 2767.
19. Cohen JL, Lacroix-Desmazes S, Charlotte F, et al. Immunological defects after suicide gene therapy of experimental graft-versus-host disease. Hum Gene Ther 1999; 10: 2701.